Free Trial
NASDAQ:BDSX

Biodesix (BDSX) Stock Price, News & Analysis

Biodesix logo
$0.31 -0.01 (-1.93%)
As of 03:01 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Biodesix Stock (NASDAQ:BDSX)

Key Stats

Today's Range
$0.30
$0.32
50-Day Range
$0.22
$0.53
52-Week Range
$0.17
$2.04
Volume
498,951 shs
Average Volume
2.46 million shs
Market Capitalization
$45.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.75
Consensus Rating
Moderate Buy

Company Overview

Biodesix Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

BDSX MarketRank™: 

Biodesix scored higher than 68% of companies evaluated by MarketBeat, and ranked 307th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Biodesix has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Biodesix has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Biodesix's stock forecast and price target.
  • Earnings Growth

    Earnings for Biodesix are expected to grow in the coming year, from ($0.35) to ($0.24) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Biodesix is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Biodesix is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Biodesix has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Biodesix's valuation and earnings.
  • Percentage of Shares Shorted

    5.13% of the float of Biodesix has been sold short.
  • Short Interest Ratio / Days to Cover

    Biodesix has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Biodesix has recently decreased by 6.57%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Biodesix does not currently pay a dividend.

  • Dividend Growth

    Biodesix does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.13% of the float of Biodesix has been sold short.
  • Short Interest Ratio / Days to Cover

    Biodesix has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Biodesix has recently decreased by 6.57%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 2 people have searched for BDSX on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Biodesix to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Biodesix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $979.00 in company stock.

  • Percentage Held by Insiders

    30.10% of the stock of Biodesix is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 20.96% of the stock of Biodesix is held by institutions.

  • Read more about Biodesix's insider trading history.
Receive BDSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter.

BDSX Stock News Headlines

Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
See More Headlines

BDSX Stock Analysis - Frequently Asked Questions

Biodesix's stock was trading at $1.53 at the beginning of 2025. Since then, BDSX shares have decreased by 79.5% and is now trading at $0.3130.

Biodesix, Inc. (NASDAQ:BDSX) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). The business earned $17.96 million during the quarter, compared to analysts' expectations of $19.50 million. Biodesix had a negative net margin of 54.28% and a negative trailing twelve-month return on equity of 167.28%.
Read the conference call transcript
.

Biodesix (BDSX) raised $76 million in an initial public offering (IPO) on Wednesday, October 28th 2020. The company issued 4,200,000 shares at $17.00-$19.00 per share. Morgan Stanley and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biodesix investors own include Broadcom (AVGO), NVIDIA (NVDA), Adobe (ADBE), Arista Networks (ANET), ServiceNow (NOW), CrowdStrike (CRWD) and Meta Platforms (META).

Company Calendar

Last Earnings
5/13/2025
Today
7/10/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical Services
Sub-Industry
Healthcare
Current Symbol
NASDAQ:BDSX
CIK
1439725
Fax
N/A
Employees
220
Year Founded
N/A

Price Target and Rating

High Price Target
$2.00
Low Price Target
$1.50
Potential Upside/Downside
+466.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$42.93 million
Pretax Margin
-54.28%

Debt

Sales & Book Value

Annual Sales
$71.32 million
Price / Cash Flow
N/A
Book Value
$0.14 per share
Price / Book
2.21

Miscellaneous

Free Float
102,448,000
Market Cap
$45.29 million
Optionable
Optionable
Beta
0.97
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:BDSX) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners